Lexaria’s Diabetes Study Results Feature Weight Loss and Improved Triglyceride and Cholesterol Levels
Lexaria Bioscience (NASDAQ: LEXX) shared the notable results of its recent diabetes animal model study, with positive outcomes including weight loss and improved triglyceride and cholesterol levels in obese diabetic-conditioned animals who were dosed with DehydraTECH-CBD. The growing global diabetes drug market is anticipated to reach nearly $83 billion by 2027, and the bioscience company’s stock rose 5% premarket with the news.
Diabetes, a chronic health condition that occurs when blood sugar is too high, includes complications ranging from heart disease to stroke, kidney failure and vision loss. Many patients prefer drugs rather than the pain of insulin injections, creating a significant market for drugs such as Lexaria’s DehydraTECH-CBD, which improved day-to-day health in the lab animals studied, particularly at the lower dosage studied.
Ozempic and Wegovy have dominated headlines (and TikToks) recently as the diabetes drug and its weight-loss counterpart have faced global shortages after gaining social media fame for their ability to spur weight loss. Both drugs are injected.
Three positive outcomes in first animal study
In study DIAB-A22-1, obese rats began losing weight just four days after DehydraTECH-CBD dosing, with weight loss maintained throughout the eight-week study. The weight of untreated animals trended upwards while those dosed with DehydraTECH-CBD lost an average of 7% body weight. Further, weight loss was not related to reduced food or water intake, which were comparable across all groups.
In addition, obese animals that received DehydraTECH-CBD saw statistically significant reductions in triglyceride levels beginning at five weeks, achieving a 25% reduction compared to untreated animals. Two doses of DehydraTECH-CBD were studied, and the lower dosage outperformed the higher one in this category. Higher triglyceride levels can indicate the onset of diabetes, so the ability to manage and reduce them is critical. Finally, the lower dose increased HDL “good” cholesterol, but didn’t affect LDL “bad” cholesterol in the study.
Lexaria’s recent study aligns with previous research on CBD’s anti-inflammatory properties as related to diabetes. This was the company’s first study of DehydraTECH-CBD in obese diabetic-conditioned animals.
Disclaimer
This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
